Wednesday - January 07, 2026

Category Archives: Financial Market

SaverOne (Nasdaq: SVRE ) Announces Strategic LOI with AI Defense Stock VisionWave Holdings ( Nasdaq: VWAV) for Collaboration in Defense and Security Sector

Investorideas.com, a top 100 rated investment site for retail Investors following AI, tech and defense stocks, reports on breaking news for VisionWave Holdings, Inc (Nasdaq: VWAV) and SaverOne 2014 Ltd. (Nasdaq: SVRE) (TASE: SVRE). SaverOne 2014 Ltd. (Nasdaq: SVRE) (TASE: SVRE), … Continue reading →

Kartoon Studios (NYSE: TOON) Expansion Fuels 2026-2027 Upside – DVLT, UFG, VRME, ARBE More Inside

Kartoon Studios (NYSE: TOON) global content ecosystem as Mainframe Studios, Toon Media Networks, and its high-profile IP pipeline continue to fuel long-term growth. Mainframe Studios, one of North America’s largest animation producers, posted another record quarter, with revenue surging 45% … Continue reading →

Scienjoy (NASDAQ: SJ): Asymmetric Upside Into 2026 – among MOBX, MKDW, SOWG More Inside

The market continues to misprice Scienjoy’s (NASDAQ: SJ) sum-of-the-parts story, creating a compelling setup as the company enters a potentially pivotal 2026 growth phase. At current trading levels (~0.22x P/B, ~0.2x EV/Sales), Scienjoy’s China livestreaming business alone largely justifies the … Continue reading →

2026 Golden Visa Update: Investment Migration Industry Faces Rising Wave of Sophisticated Fraud, Warns New Industry Report

As the global investment migration market continues its expansion beyond $20 billion in annual revenue, a comprehensive new analysis reveals an alarming surge in fraudulent schemes targeting unsuspecting investors seeking citizenship and residency through investment programs. The report exposes a … Continue reading →

Nika Pharmaceuticals (OTCQB: NIKA) Targets Immune Health Breakthroughs Across HIV, Cancer, and Chronic Diseases

Nika Pharmaceuticals, Inc. (OTCQB: NIKA) is gaining investor attention as a next-generation biopharmaceutical company developing advanced immune-strengthening therapeutics for some of the world’s most critical diseases, including HIV/AIDS, Hepatitis B and C, Rheumatoid Arthritis, Cancer, and Diabetes. The company’s intellectual … Continue reading →